JP2015517525A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015517525A5 JP2015517525A5 JP2015512779A JP2015512779A JP2015517525A5 JP 2015517525 A5 JP2015517525 A5 JP 2015517525A5 JP 2015512779 A JP2015512779 A JP 2015512779A JP 2015512779 A JP2015512779 A JP 2015512779A JP 2015517525 A5 JP2015517525 A5 JP 2015517525A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- pharmaceutical composition
- acceptable salt
- composition
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261648110P | 2012-05-17 | 2012-05-17 | |
| US61/648,110 | 2012-05-17 | ||
| PCT/US2013/041076 WO2013173417A2 (en) | 2012-05-17 | 2013-05-15 | Glucokinase activator compositions for the treatment of diabetes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015517525A JP2015517525A (ja) | 2015-06-22 |
| JP2015517525A5 true JP2015517525A5 (enExample) | 2016-06-30 |
| JP6234443B2 JP6234443B2 (ja) | 2017-11-22 |
Family
ID=48576527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015512779A Active JP6234443B2 (ja) | 2012-05-17 | 2013-05-15 | 糖尿病治療のためのグルコキナーゼ活性化因子組成物 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10004782B2 (enExample) |
| EP (1) | EP2849776B1 (enExample) |
| JP (1) | JP6234443B2 (enExample) |
| KR (2) | KR102371364B1 (enExample) |
| CN (2) | CN118453592A (enExample) |
| AU (2) | AU2013262895A1 (enExample) |
| BR (1) | BR112014028622A2 (enExample) |
| CA (1) | CA2872021C (enExample) |
| EA (1) | EA201492109A1 (enExample) |
| ES (1) | ES2878001T3 (enExample) |
| HK (1) | HK1202458A1 (enExample) |
| IL (1) | IL235484A0 (enExample) |
| IN (1) | IN2014DN09554A (enExample) |
| MX (1) | MX360304B (enExample) |
| SG (2) | SG10201609644UA (enExample) |
| WO (1) | WO2013173417A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102906077B (zh) | 2010-05-26 | 2015-03-04 | 转化技术制药有限责任公司 | 二甲双胍与葡萄糖激酶激活剂的联合使用以及包含二甲双胍和葡萄糖激酶激活剂的组合物 |
| KR102371364B1 (ko) | 2012-05-17 | 2022-03-07 | 브이티브이 테라퓨틱스 엘엘씨 | 당뇨병 치료를 위한 글루코키나아제 활성화제 조성물 |
| KR102408480B1 (ko) | 2018-05-30 | 2022-06-10 | 이삼구 | 당뇨질환의 치료용 조성물 |
| JP7265276B2 (ja) | 2018-05-31 | 2023-04-26 | 華領医薬技術（上海）有限公司 | グルコキナーゼ活性化剤およびｓｇｌｔ－２阻害薬を含む医薬品の組合せ、組成物、配合剤、ならびにその調製方法および使用 |
| JP2021526130A (ja) * | 2018-06-12 | 2021-09-30 | ブイティーブイ・セラピューティクス・エルエルシー | インスリンまたはインスリン類似体と組み合わせたグルコキナーゼ活性化薬の治療的使用 |
| US11872221B2 (en) | 2020-01-31 | 2024-01-16 | Hua Medicine (Shanghai) Ltd. | Treating untreated or treatment-resistant diabetes with glucokinase activator |
| CA3169432A1 (en) * | 2020-01-31 | 2021-08-05 | Hua Medicine (Shanghai) Ltd. | Treating treatment-resistant diabetes with glucokinase activator |
| WO2021167840A1 (en) | 2020-02-18 | 2021-08-26 | Vtv Therapeutics Llc | Sulfoxide and sulfone glucokinase activators and methods of use thereof |
| US11857536B2 (en) | 2020-06-04 | 2024-01-02 | Hua Medicine (Shanghai) Ltd. | Glucokinase activator for treating diabetes with renal impairment |
| CA3185831A1 (en) * | 2020-06-04 | 2021-12-09 | Hua Medicine (Shanghai) Ltd. | Glucokinase activator for treating diabetes with renal impairment |
| WO2021243646A1 (en) * | 2020-06-04 | 2021-12-09 | Hua Medicine (Shanghai) Ltd. | Glucokinase activator for treating diabetes with hepatic impairment |
| CN116056760A (zh) * | 2020-06-08 | 2023-05-02 | 维特卫治疗有限责任公司 | {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的结晶形式及其用途 |
| US12479808B2 (en) | 2020-06-08 | 2025-11-25 | Vtv Therapeutics Llc | Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof |
| CN115350268B (zh) * | 2022-08-24 | 2025-02-11 | 深圳青澜生物技术有限公司 | 一种用于治疗糖尿病的制剂、微针及其制备工艺 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT323195B (de) | 1973-03-16 | 1975-06-25 | Hurka Wilhelm | Verfahren zur herstellung neuer salze von biguaniden |
| FR2243684B1 (enExample) | 1973-09-19 | 1977-01-28 | Semb | |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5552160A (en) | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
| US6794412B1 (en) * | 1999-03-11 | 2004-09-21 | Bristol-Myers Squibb Pharma Company | Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin |
| DE60036367T2 (de) * | 1999-06-21 | 2008-05-29 | Eli Lilly And Co., Indianapolis | Synergitische verwendung von thiazolidinedionen und glucagon-ähnlichem peptid-1 und dessen agonisten für die behandlung von nicht-insulin-abhängigen diabetes |
| US6294546B1 (en) * | 1999-08-30 | 2001-09-25 | The Broad Of Trustees Of The Leland Stanford Junior University | Uses of diterpenoid triepoxides as an anti-proliferative agent |
| US6608038B2 (en) * | 2000-03-15 | 2003-08-19 | Novartis Ag | Methods and compositions for treatment of diabetes and related conditions via gene therapy |
| CA2488642C (en) | 2002-06-27 | 2011-09-06 | Dharma Rao Polisetti | Aryl carbonyl derivatives as glucokinase activators |
| MXPA05009059A (es) | 2003-02-26 | 2005-10-19 | Banyu Pharma Co Ltd | Derivados de heteroarilcarbamoilbenceno. |
| KR20060052650A (ko) * | 2003-07-14 | 2006-05-19 | 소니 가부시끼 가이샤 | 정보제공방법 |
| WO2005023766A1 (en) | 2003-09-11 | 2005-03-17 | Biocon Limited | Salt of atorvastatin with metformin |
| PL1723128T3 (pl) * | 2004-01-06 | 2013-04-30 | Novo Nordisk As | Pochodne heteroarylowe mocznika oraz ich zastosowanie jako aktywatory glukokinazy |
| CN1910166B (zh) * | 2004-01-06 | 2012-01-04 | 诺和诺德公司 | 杂芳基脲及其作为葡糖激酶活化剂的用途 |
| JP2008502658A (ja) * | 2004-06-17 | 2008-01-31 | ノボ ノルディスク アクティーゼルスカブ | 肝臓選択的グルコキナーゼ活性化因子の使用 |
| WO2006110809A2 (en) | 2005-04-12 | 2006-10-19 | Elan Pharma International, Limited | Nanoparticulate lipase inhibitor formulations |
| US20100028439A1 (en) | 2005-05-23 | 2010-02-04 | Elan Pharma International Limited | Nanoparticulate stabilized anti-hypertensive compositions |
| CN101258137A (zh) * | 2005-07-08 | 2008-09-03 | 诺沃-诺迪斯克有限公司 | 双环烷基脲葡糖激酶活化剂 |
| WO2007006760A1 (en) | 2005-07-08 | 2007-01-18 | Novo Nordisk A/S | Dicycloalkyl urea glucokinase activators |
| JP2009500378A (ja) | 2005-07-08 | 2009-01-08 | ノボ・ノルデイスク・エー／エス | グルコキナーゼ活性化剤としてのジシクロアルキルカルバモイル尿素 |
| MX2008000255A (es) | 2005-07-14 | 2008-04-02 | Novo Nordisk As | Activadores de urea glucocinasa. |
| JP5419706B2 (ja) | 2006-12-20 | 2014-02-19 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼアクチベーター |
| EP2118083A1 (en) | 2007-01-09 | 2009-11-18 | Novo Nordisk A/S | Urea glucokinase activators |
| WO2009140624A2 (en) | 2008-05-16 | 2009-11-19 | Takeda San Diego, Inc. | Glucokinase activators |
| WO2010010760A1 (ja) | 2008-07-22 | 2010-01-28 | 株式会社クレハ | 末端ハロゲン基含量が低減されたポリアリーレンスルフィドの製造方法 |
| WO2010107610A1 (en) * | 2009-03-17 | 2010-09-23 | Merck Sharp & Dohme Corp. | Method for treatment of diabetes and related conditions with combination therapy and compositions containing such compounds |
| TW201103534A (en) | 2009-04-16 | 2011-02-01 | Taisho Pharmaceutical Co Ltd | Pharmaceutical compositions |
| WO2011025270A2 (ko) | 2009-08-25 | 2011-03-03 | 한올바이오파마주식회사 | 메트포르민 카페익산염, 그의 제조방법, 그를 포함하는 약학조성물 및 그를 포함하는 복합제제 |
| CN102906077B (zh) | 2010-05-26 | 2015-03-04 | 转化技术制药有限责任公司 | 二甲双胍与葡萄糖激酶激活剂的联合使用以及包含二甲双胍和葡萄糖激酶激活剂的组合物 |
| EP2392575A1 (en) * | 2010-06-04 | 2011-12-07 | LEK Pharmaceuticals d.d. | A novel synthetic approach to ß-aminobutyryl substituted compounds |
| KR102371364B1 (ko) * | 2012-05-17 | 2022-03-07 | 브이티브이 테라퓨틱스 엘엘씨 | 당뇨병 치료를 위한 글루코키나아제 활성화제 조성물 |
| CN105188676A (zh) | 2013-03-04 | 2015-12-23 | Vtv治疗有限责任公司 | 包括葡糖激酶活化剂的固体组合物及其制备和使用方法 |
| KR20150123838A (ko) | 2013-03-04 | 2015-11-04 | 브이티브이 테라퓨틱스 엘엘씨 | 안정한 글루코키나제 활성화제 조성물 |
-
2013
- 2013-05-15 KR KR1020217006420A patent/KR102371364B1/ko active Active
- 2013-05-15 KR KR1020147035545A patent/KR20150013838A/ko not_active Ceased
- 2013-05-15 MX MX2014013105A patent/MX360304B/es active IP Right Grant
- 2013-05-15 SG SG10201609644UA patent/SG10201609644UA/en unknown
- 2013-05-15 SG SG11201406987UA patent/SG11201406987UA/en unknown
- 2013-05-15 EA EA201492109A patent/EA201492109A1/ru unknown
- 2013-05-15 HK HK15103235.2A patent/HK1202458A1/xx unknown
- 2013-05-15 WO PCT/US2013/041076 patent/WO2013173417A2/en not_active Ceased
- 2013-05-15 IN IN9554DEN2014 patent/IN2014DN09554A/en unknown
- 2013-05-15 BR BR112014028622A patent/BR112014028622A2/pt not_active Application Discontinuation
- 2013-05-15 CN CN202410499223.0A patent/CN118453592A/zh active Pending
- 2013-05-15 CN CN201380024802.XA patent/CN104349790A/zh active Pending
- 2013-05-15 AU AU2013262895A patent/AU2013262895A1/en not_active Abandoned
- 2013-05-15 ES ES13726933T patent/ES2878001T3/es active Active
- 2013-05-15 CA CA2872021A patent/CA2872021C/en active Active
- 2013-05-15 EP EP13726933.8A patent/EP2849776B1/en active Active
- 2013-05-15 JP JP2015512779A patent/JP6234443B2/ja active Active
- 2013-11-05 US US14/071,976 patent/US10004782B2/en active Active
-
2014
- 2014-11-03 IL IL235484A patent/IL235484A0/en unknown
-
2017
- 2017-06-07 AU AU2017203835A patent/AU2017203835B2/en active Active
-
2018
- 2018-05-18 US US15/983,249 patent/US10588943B2/en active Active
-
2020
- 2020-01-16 US US16/744,956 patent/US10980861B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015517525A5 (enExample) | ||
| JP2013529617A5 (enExample) | ||
| JP2016510795A5 (enExample) | ||
| Cornell | A review of GLP‐1 receptor agonists in type 2 diabetes: a focus on the mechanism of action of once‐weekly agents | |
| JP2015520155A5 (enExample) | ||
| JP6293897B2 (ja) | ネコ科動物の代謝異常の治療 | |
| RU2443691C2 (ru) | Мочевинные активаторы глюкокиназы | |
| Mittermayer et al. | Addressing unmet medical needs in type 2 diabetes: a narrative review of drugs under development | |
| Ahrén et al. | The islet enhancer vildagliptin: mechanisms of improved glucose metabolism | |
| FI2981255T3 (fi) | Empagliflotsiinin terapeuttiset käytöt | |
| EA200800198A1 (ru) | Способы предупреждения и лечения метаболических нарушений и новые производные пиразол-о-гликозида | |
| AR078517A1 (es) | Composicion farmaceutica, forma de dosificacion farmaceutica, procedimiento para su preparacion, metodos para su tratamiento y sus usos | |
| EA201892383A1 (ru) | Композиция для лечения диабета или диажирения, содержащая аналог оксинтомодулина | |
| HRP20191713T1 (hr) | Pripravci, uporabe i metode za liječenje metaboličkih poremećaja i bolesti | |
| JP2013532644A5 (enExample) | ||
| JP2011503152A5 (enExample) | ||
| JP2013199503A5 (enExample) | ||
| NZ598318A (en) | Method for the preparation of a crystalline form of 1-chloro-4- (beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene | |
| WO2007112069A3 (en) | Endothelin and endothelin receptor agonists in the treatment of metabolic diseases | |
| CN102906077B (zh) | 二甲双胍与葡萄糖激酶激活剂的联合使用以及包含二甲双胍和葡萄糖激酶激活剂的组合物 | |
| TW201304783A (zh) | 治療代謝疾病之醫藥組合 | |
| JP2017508794A5 (enExample) | ||
| Parlevliet et al. | GLP-1 treatment reduces endogenous insulin resistance via activation of central GLP-1 receptors in mice fed a high-fat diet | |
| WO2012051567A3 (en) | Obesity-related genes and their proteins and uses thereof | |
| MX2014002471A (es) | Combinaciones sinergicas de los inhibidores de p13k y mek. |